MiMedx Group (MDXG)
(Delayed Data from NSDQ)
$6.26 USD
-0.01 (-0.16%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $6.26 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
MiMedx Group, Inc [MDXG]
Reports for Purchase
Showing records 1 - 20 ( 23 total )
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
LCD Proposal Creates Headwind for EPIEFFECT Despite Strong 1Q Revenue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Positioning for Long Term Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for MDXG 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Profitability Achieved; Multiple Drivers to Sustain Long-Term Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Wound Surgical Revenues Growth Ensures Profitability in 2H; New $11 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Strategic Realignment to Focus on Wound Surgical Business; Expect Positive EPS in 2H23; Lower $8 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Strong start to 2023; New $9.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Achieve Profitability in 2023; Long-Term Thesis Intact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Awaiting CMS Town Hall for Clarity on Reimbursement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
New CEO Leads with Strategic Initiatives; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
A Softer 3Q22 Expected; CEO Transition Initiated; PT Adjusted to $8; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Multiple Launches Upcoming in 3Q22; KOA Study on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Growth in Core Business Driving 2022 Revenues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Japanese Launch Upcoming; KOA Pivotal Study to Start in 2H22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Outlook for 2022 and Beyond Appears Positive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Focus Remains on KOA Indication; Japanese and Product Launches to Drive Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Core Business Remains Strong; Investor Day in December; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
mdHACM Fails PF; Hope For KOA Continues; Lower PT to $8.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MiMedx Group, Inc
Industry: Medical - Biomedical and Genetics
Awaiting Major Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S